You have access
Prognostic Benefit of ≥6 Cycles of Neoadjuvant Chemotherapy for Advanced Ovarian, Tubal, and Peritoneal Cancers
EIJI KONDO, RYO NIMURA, SHINTARO MAKI, MICHIKO KANEDA, MASAFUMI NII, KENTA YOSHIDA, TSUTOMU TABATA and TOMOAKI IKEDA
Anticancer Research August 2021, 41 (8) 4157-4161; DOI: https://doi.org/10.21873/anticanres.15219